Page last updated: 2024-08-21

pyrazines and ly2603618

pyrazines has been researched along with ly2603618 in 18 studies

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's15 (83.33)24.3611
2020's3 (16.67)2.80

Authors

AuthorsStudies
Anthony, SP; Donehower, RC; Hurt, K; Hynes, SM; Iyengar, T; Lewandowski, K; McKane, S; Ramanathan, RK; Weiss, GJ; Westin, E1
Buck, SA; Caldwell, JT; Edwards, H; Ge, Y; Qing, WY; Taub, JW; Wang, G; Wang, Z1
Barda, D; Barnard, D; Blosser, W; Clawson, D; Cox, K; Diaz, H; Guo, S; King, C; Marshall, M1
Abraham, TL; Cassidy, KC; Chana, E; Hynes, SM; Jost, LM; Mitchell, MI; Palmieri, MD; Rehmel, JF; Wickremsinhe, ER1
Cui, YJ; Fei, HR; Li, ZM; Sun, BL; Sun, YK; Wang, FZ; Wang, XY; Yang, XY; Zhang, JG1
Barnard, D; Calles, A; Calvo, E; Chen, VJ; Diaz, HB; Dickgreber, N; Huber, L; Hynes, SM; Iversen, P; Kays, L; Kumm, E; Lin, AB; Marshall, M; Merzoug, FF; Ohnmacht, U; Sebastian, M; Voss, B; Wehler, T1
Chandler, J; Decker, R; Hynes, SM; Mitchell, M; Ott, J; Wickremsinhe, E; Zhang, W1
Doi, T; Fuse, N; Hynes, SM; Lin, AB; Matsubara, N; Naito, Y; Nakamura, T; Shitara, K; Uenaka, K; Yoshino, T1
Barda, D; Barnard, D; Beckmann, R; Burke, T; Diaz, HB; Donoho, G; Jones, B; King, C; Marshall, M1
Edwards, H; Ge, Y; Li, X; Lin, H; Niu, X; Taub, JW; Wang, G; Wang, Y; Zhao, J1
Deng, O; Du, Z; Gao, J; Gorityala, S; Lai, J; Ma, Z; Susana, G; Xiong, X; Xu, Y; Yan, C; Yang, S; Zhang, J; Zhang, Y1
Boyd, TE; Hynes, SM; Kang, JH; Kim, SW; Lin, AB; Lin, J; Myrand, SP; Novello, S; Park, K; Pinder-Schenck, M; Richards, DA; Rosenberg, R; Scagliotti, G; Smith, D; Smyth, EN; Su, WC; Wijayawardana, S1
Becerra, C; Bence Lin, A; Braiteh, F; Calvo, E; Galsky, MD; Hurt, K; Hynes, SM; Jameson, G; Lin, J; McKane, S; McWilliams, R; Richards, D; Von Hoff, D; Wickremsinhe, ER1
Hasvold, G; Hauge, S; Joel, M; Juzenas, P; Naucke, C; Rødland, GE; Stokke, T; Syljuåsen, RG1
Benes, CH; Borgmann, K; Dinkelborg, PH; Gheorghiu, L; Gurski, JM; Hong, TS; Jimenez, RB; Juric, D; Wang, M; Willers, H1
Bajzikova, M; Boukalova, S; Coelho, A; Davidova, E; Ditzel, HJ; Hubackova, S; Kovarova, J; Neuzil, J; Rohlena, J; Terp, MG1
Ju, JQ; Li, XH; Pan, MH; Sun, MH; Sun, SC; Xu, Y1
Arthur, J; Conti, DJ; Friedrich, TD; Hainley, LE; Hayner-Buchan, A; Hughson, MS; Lehman, JM; Narendran, A; Smith, R1

Trials

6 trial(s) available for pyrazines and ly2603618

ArticleYear
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer.
    Investigational new drugs, 2013, Volume: 31, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Female; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pemetrexed; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines

2013
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.
    Investigational new drugs, 2014, Volume: 32, Issue:5

    Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; DNA; Female; Glutamates; Guanine; Humans; Male; Mice, Nude; Middle Aged; Neoplasms; Pemetrexed; Phenylurea Compounds; Pyrazines; Tumor Burden; Xenograft Model Antitumor Assays

2014
Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.
    Biopharmaceutics & drug disposition, 2015, Volume: 36, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Area Under Curve; Checkpoint Kinase 1; Computer Simulation; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Desipramine; Drug Interactions; Female; Humans; Infusions, Intravenous; Least-Squares Analysis; Male; Middle Aged; Neoplasms; Phenylurea Compounds; Protein Kinases; Pyrazines; Young Adult

2015
Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors.
    Anti-cancer drugs, 2015, Volume: 26, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines

2015
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.
    Investigational new drugs, 2016, Volume: 34, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Checkpoint Kinase 1; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome; Tumor Suppressor Protein p53

2016
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.
    Oncology, 2016, Volume: 91, Issue:5

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Fatigue; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Phenylurea Compounds; Pyrazines; Thrombocytopenia; Young Adult

2016

Other Studies

12 other study(ies) available for pyrazines and ly2603618

ArticleYear
Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
    PloS one, 2013, Volume: 8, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; G2 Phase Cell Cycle Checkpoints; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Neuroblastoma; Panobinostat; Phenylurea Compounds; Protein Kinases; Pyrazines

2013
Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.
    Investigational new drugs, 2014, Volume: 32, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Doxorubicin; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Tumor Suppressor Protein p53

2014
Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors.
    Xenobiotica; the fate of foreign compounds in biological systems, 2014, Volume: 44, Issue:9

    Topics: Administration, Intravenous; Aged; Chromatography, Liquid; Dose-Response Relationship, Drug; Drug Interactions; Feces; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Microsomes, Liver; Middle Aged; Neoplasms; Phenylurea Compounds; Pyrazines; Tandem Mass Spectrometry

2014
The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
    Apoptosis : an international journal on programmed cell death, 2014, Volume: 19, Issue:9

    Topics: Antineoplastic Agents; Antirheumatic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Chloroquine; DNA Damage; DNA Repair; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; MAP Kinase Kinase 4; Nuclear Proteins; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Serine

2014
LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
    Investigational new drugs, 2016, Volume: 34, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Colonic Neoplasms; Deoxycytidine; DNA Damage; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Xenograft Model Antitumor Assays

2016
Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
    Oncotarget, 2016, Jun-07, Volume: 7, Issue:23

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Checkpoint Kinase 1; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; G2 Phase Cell Cycle Checkpoints; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mitosis; Myeloid Cell Leukemia Sequence 1 Protein; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides; THP-1 Cells; U937 Cells

2016
Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress.
    Oncotarget, 2016, Jun-07, Volume: 7, Issue:23

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; DNA Repair; Homologous Recombination; Humans; MCF-7 Cells; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents; Thiophenes; Urea

2016
Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
    Oncotarget, 2017, Feb-14, Volume: 8, Issue:7

    Topics: A549 Cells; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Cyclin-Dependent Kinases; DNA Damage; DNA Replication; Drug Synergism; Flow Cytometry; Humans; Nuclear Proteins; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Pyrimidinones; S Phase; Thiophenes; Urea

2017
A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types.
    Breast cancer research and treatment, 2019, Volume: 174, Issue:3

    Topics: Adenocarcinoma of Lung; Biopsy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; DNA Breaks, Double-Stranded; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Leukemic; Humans; Lung Neoplasms; MCF-7 Cells; Mutation; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents; Small Molecule Libraries; Triple Negative Breast Neoplasms

2019
Replication and ribosomal stress induced by targeting pyrimidine synthesis and cellular checkpoints suppress p53-deficient tumors.
    Cell death & disease, 2020, 02-07, Volume: 11, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Checkpoint Kinase 1; Dihydroorotate Dehydrogenase; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-2; HCT116 Cells; Humans; Leflunomide; MCF-7 Cells; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Oxidoreductases Acting on CH-CH Group Donors; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Ribosomes; Signal Transduction; Tumor Suppressor Protein p53

2020
CHK1 monitors spindle assembly checkpoint and DNA damage repair during the first cleavage of mouse early embryos.
    Cell proliferation, 2020, Volume: 53, Issue:10

    Topics: Animals; Apoptosis; Aurora Kinase B; Cell Cycle Proteins; Checkpoint Kinase 1; Chromosome Segregation; DNA Damage; DNA Repair; Embryo, Mammalian; Embryonic Development; Kinetochores; M Phase Cell Cycle Checkpoints; Mice; Microtubules; Oxidative Stress; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyrazines; Reactive Oxygen Species

2020
Chk1 and the Host Cell DNA Damage Response as a Potential Antiviral Target in BK Polyomavirus Infection.
    Viruses, 2021, 07-13, Volume: 13, Issue:7

    Topics: BK Virus; Cells, Cultured; Checkpoint Kinase 1; DNA Damage; DNA Repair; Humans; Kidney; Kidney Transplantation; Phenylurea Compounds; Polyomavirus Infections; Pyrazines; Tumor Virus Infections; Virus Replication

2021